Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution
- OTC: 0.012%
- OTC: 0.02%
- 0.1%
Ocular Vasoconstrictor/Decongestant
Temporary relief of ocular redness caused by irritation & relief of burning or irritation caused by dry eyes
0.1% solution: 1-2 gtt to affected eye q3-4hr PRN
0.012% or 0.025% solution: 1-2 gtt to affected eye(s); not to exceed q6hr; therapy not to exceed 72 hours of use
Dosage Forms & Strengths
ophthalmic solution
- OTC: 0.012%
- 0.03%
- 0.1%
Ocular Vasoconstrictor/Decongestant
Safety & efficacy not established
Adverse Effects
Frequency Not Defined
Blurred vision
Mild transient stinging and/or irritation
Mydriasis
Increased or decreased intraocular pressure
Headache
Warnings
Contraindications
Narrow angle glaucoma
Anatomic narrow angle
Hypersensitivity
Cautions
Use with caution in patients with hypertension, cardiovascular abnormalities, diabetes mellitus, hyperthyroidism, infection, or injury
Stop use if vision changes, eye pain, or condition worsens
Concurrent use with MAO inhibitors may cause hypertensive crisis
Use in children, especially infants, may result in CNS depression leading to coma and marked reduction in body temperature
Advice patients to discontinue drug and consult physician if relief not obtained within 48 hours of therapy, if irritation, blurring or redness persists or increases, or if symptoms of systemic absorption occur, eg, dizziness, headache, nausea, decrease in body temperature, or drowsiness
To prevent contaminating dropper tip and solution, do not touch any surface, the eyelids or surrounding area with dropper tip of the bottle; if solution changes color or becomes cloudy, do not use
Drug interaction overview
- Concurrent use of maprotiline or tricyclic antidepressants may potentiate the pressor effect of naphazoline; patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug
Pregnancy & Lactation
Pregnancy
Animal reproduction studies not conducted; it is not known whether this drug can cause harm when administered to pregnant women or can affect reproduction capacity; administer to a pregnant women only if clearly needed
Lactation
Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, use caution when therapy administered to nursing women
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
May produce vasoconstriction by stimulating alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa
May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants
Pharmcokinetics
Absorption: Minimal (systemic)
Onset: Within 10 min
Duration: 2-6 hr
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.